These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18090962)

  • 1. Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease.
    Basile JN
    South Med J; 2007 Dec; 100(12):1200-7. PubMed ID: 18090962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
    Berns JS
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress in uremia: the role of anemia correction.
    Lahera V; Goicoechea M; de Vinuesa SG; Oubiña P; Cachofeiro V; Gómez-Campderá F; Amann R; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S174-7. PubMed ID: 17130258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal anemia syndrome in chronic kidney disease.
    Tarng DC
    J Chin Med Assoc; 2007 Oct; 70(10):424-9. PubMed ID: 17962140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anemia in chronic kidney disease and its cardiovascular implications].
    Cases A; Coll E; Collado S
    Med Clin (Barc); 2009 May; 132 Suppl 1():38-42. PubMed ID: 19460479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4].
    Choukroun G; Renou M; Lecaque C; Jauréguy M
    Nephrol Ther; 2011 Feb; 7(1):2-9. PubMed ID: 21216683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia in renal disease: diagnosis and management.
    Lankhorst CE; Wish JB
    Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
    Desai AS; Toto R; Jarolim P; Uno H; Eckardt KU; Kewalramani R; Levey AS; Lewis EF; McMurray JJ; Parving HH; Solomon SD; Pfeffer MA
    Am J Kidney Dis; 2011 Nov; 58(5):717-28. PubMed ID: 21820220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.
    Bacchus S; O'Mara N; Manley H; Fishbane S
    Ann Pharmacother; 2009 Nov; 43(11):1857-66. PubMed ID: 19826095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attitude of physicians in Saudi Arabia towards anemia treatment strategies in patients with chronic kidney disease.
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):65-72. PubMed ID: 17237894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K; Hirakata H
    Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical relevance of anemia treatment in patients with chronic kidney disease].
    Vuksanović-Mikulicić S; Mikolasević I; Jelić I; Bubić I; Sladoje-Martinović B; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):193-202. PubMed ID: 23441533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
    Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An expert opinion on the current treatment of anemia in patients with kidney disease.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.